Back to search results

Apixaban for Preventing Blood Clots in Glioma Patients

This study is looking at how safe a medication called apixaban is for preventing blood clots (venous thromboembolism or VTE) in people with newly diagnosed grade 4 glioma, which includes glioblastoma and astrocytoma. You might be able to join if you are 18 or older, have a specific type of malignant glioma, and meet certain health requirements like acceptable blood test results. The main goal is to see how safe apixaban is by checking for bleeding risks over 6 months. The study is currently unclear on its recruitment status and plans to enroll about 40 participants.

Study design
This is an open-label study, meaning both you and your doctors will know you are receiving apixaban. It plans to enroll about 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be checked for bleeding risks over 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05683808

Venous Thromboembolism Prevention in Outpatients With Glioma

Recruiting
PHASE2Ages 18+InterventionalSupportive care
University of Vermont Medical Center
~40 participants
Updated 2026-01-30 on ClinicalTrials.gov
What's tested:Apixaban

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety of apixaban as determined by bleeding risk
Measured over 6 months

Conditions

Glioblastoma
Astrocytoma
Venous Thromboembolism

Explore related trials

AstrocytomaGlioblastoma

Where it's being run

1 sites across 1 states
Vermont1

Study leadership

  • Alissa A Thomas, MD · PRINCIPAL_INVESTIGATOR · University of Vermont Medical Center

Who to contact

Alissa A Thomas, MD
[email protected]
802-847-8400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.
Age 18 and old
Karnofsky performance status (KPS) 60-100
Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
Ability to provide informed consent.
Planning for treatment with radiation and chemotherapy.

Exclusion

Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.
Pregnancy.
Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours.
Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples: fondaparinux), or other direct oral anticoagulants (examples: dabigatran, edoxaban, rivaroxaban), who are either unable or unable to discontinue these agents in favor of the investigational drug. Apixaban is also contraindicated in patients who are on strong CYP3A4 inhibitor and P-glycoprotein inhibitors.
Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).
Estimated life expectancy of \<3 months.

What this trial measures

  • Safety of apixaban as determined by bleeding risk6 months

    CTCAE 5 reporting of grade 2 non-Central Nervous System (CNS) hemorrhage or grade 2 new CNS hemorrhage.